Rodrigo Dienstmann - European...
Transcript of Rodrigo Dienstmann - European...
© American Association for Cancer Research
Rodrigo Dienstmann
Oncology Data Science GroupVHIO, Barcelona, Spain
- Personal financial interests:
Advisory role: Roche, NovartisSpeaker’s fee: Roche, Symphogen, Ipsen, Amgen, SanofiDirect research fund: Merck
- Institutional financial interests:
Clinical trial support: Agendia, Amgen, Debiopharm, Janssen-Cilag, Merck, MSD,
Novartis, Pharma Mar, Roche, Sanofi, Servier, Symphogen.
Disclosure slide
3www.aacr.org/genie
Why GENIE?
More Data = More Discoveries
Data sharing
Technical, Methodological, Ethical, Legal and Cultural frame
4www.aacr.org/genie
Paradigm shift
Patient
Molecular DataGenome
SequencePhenotypic Data
Clinical Data
PublicationsData Analysis
Reanalysis of the available datafor other studies
Understandinggenomic and molecular basis of diseases
New Results disease biomarkers
Databases/RepositoriesResearch and Healthcare
centers
5www.aacr.org/genie
GENIE – Overview
§ International pancancer registry built through data sharing• Driven by openness, transparency, and inclusion
§ GOAL: improve clinical decision making• Linking clinical genotype to clinical outcomes
8 19
§ Eight founding participants, now 19• North America & Europe• Plans for future expansion
§ Sponsored research§ Collaborative projects
7www.aacr.org/genie
Institution-onlyaccess
6 months
Consortium-onlyaccess
6 months
● Data mapped to common ontology and harmonized
● Limited PHI removed● Data governance,
provenance, and versioning in a secure, HIPAA-compliant environment.
clinical queries are posed based on registry content
clinical data required to answer the question are manually abstracted
regular data uploads
genomic and clinical data linked
Consortium/sponsor-only access6 months to time of publication
A
B
DFCIIGRJHUMDAMSKNKIUHNVICCVHIO...
Clinical Sequencing
How the registry operates
www.aacr.org/genie/data
8www.aacr.org/genie
Continued Progress
0
10000
20000
30000
40000
50000
60000
70000
ene-
17
mar-1
7
may-17
jul-1
7
sep-
17
nov-
17
ene-
18
mar-1
8
may-18
jul-1
8
sep-
18
nov-
18
ene-
19
Public releases
sam
ple
s
§ Publications
• Landscape paper published in
Cancer Discovery Jun, 2017
- More than 60 citations in Oct 2018
• Review published in JCO Clinical Cancer Informatics Feb, 2018
- Most read article in July 2018,
according to publisher.
• More than 20 publications using
GENIE data as control/reference
cohort since 2017
§ Data Usage
• >5,000 individuals have requested
access to the data via cBioPortal.
• There have been six requests for
data redistribution approved; one
pending.
10www.aacr.org/genie
GENIE Today
PHENOMICSü Tumor typeü Histologyü Demographicsü Vital status
GENOMICSüSomatic Tumor DNA
60,000 Tumors 19 Cancer Centers
Data made publicly available 12 months after date of sequencing
PHENOMICSTumor typeHistologyDemographicsVital statusDetailed ClinicopathologyPrior TxOutcomes
Specific CohortsVariable # of Centers
Data made public at time of publication
Sponsored Research
11www.aacr.org/genie
Case Study – Objectives
§ Multi-center, retrospective, case controlled study describing the outcome of metastatic breast cancer patients with ERBB2 mut vs. wild type (wt).
§ Primary Endpoint: • Overall Survival (OS) from date of metastatic diagnosis
§ Secondary Endpoints:• Overall response rate (ORR) for each line of therapy after metastatic diagnosis. • Frequency and clinical impact of coexisting mutations.
12www.aacr.org/genie
Case Study – Background
ERBB2 mut are very rare across cancer types ERBB2 mut breast cancer patients respond to ERBB2 inhibitors
Hyman et al, Nature 2017www.cbioportal.org/genie
13www.aacr.org/genie
GENIE of Tomorrow
PHENOMICSü Tumor typeü Histologyü Demographicsü Vital status§ Medications§ Treatment Outcomes
OMICSüSomatic Tumor DNA§Germline DNA§cfDNA§RNA Seq§Epigenetics§Digital pathology
100,000+ Tumors 19+ Cancer Centers
Data to Drive Discoveries
15www.aacr.org/genie
Inspirational (and “down-to-earth”) leadership
Charles Sawyers, AACR GENIE
Data sharing (value-driven perspective):
- Honors the nature of medical research as a public good
- Moral obligation to society
In practice... we must guarantee that researchers are rewarded by sharing!
AND institutions get the deserved visibility!
AND Pharma companies feel engaged.